Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

Desai et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69c5e6dd09d866d76615018c — DOI: https://doi.org/10.1001/jamacardio.2023.3342

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks· 2022 · 88 citations
2. Untitled· 2014 · 1 citations
3. Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy· 2005 · 336 citations
4. Outcomes in Guideline‐Based Class I Indication Versus Earlier Referral for Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy· 2020 · 52 citations
5. Association of Septal Myectomy With Quality of Life in Patients With Left Ventricular Outflow Tract Obstruction From Hypertrophic Cardiomyopathy· 2022 · 33 citations